BPC-157 vs LL-37 for Wound Healing Research UK 2026: FAK-eNOS angiogenesis versus antimicrobial innate immunity in tissue repair biology

All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, therapeutic application, or clinical treatment. This content is directed at qualified researchers operating within applicable UK regulatory frameworks (Research Use Only).

BPC-157 and LL-37 are both extensively characterised for wound healing activity, yet they address fundamentally different aspects of the repair process. BPC-157 drives angiogenesis, fibroblast migration, tendon/ligament repair, and systemic tissue protection via FAK-eNOS-NO-VEGFR2 signalling — mechanistically oriented toward the vascular and fibroblastic components of healing. LL-37 drives antimicrobial defence, re-epithelialisation, innate immune cell recruitment, and keratinocyte proliferation — mechanistically oriented toward the epithelial and infectious components of the wound environment. Understanding this division is essential for designing experiments that cleanly attribute wound-healing outcomes to one versus the other pathway. This comparison is distinct from the TB-500 vs BPC-157 comparison (ID 77412), the BPC-157 pillar guide, and the LL-37 pillar guide.

Mechanism of Action: FAK-eNOS vs FPR2-EGFR

BPC-157 (Body Protection Compound-157, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419 Da) initiates wound healing biology through focal adhesion kinase (FAK) phosphorylation at Tyr-397 in fibroblasts and endothelial cells, independently of an identified cell-surface receptor. FAK-pY397 activates downstream: PI3K-Akt-eNOS → nitric oxide (NO) production; VEGFR2 transactivation → ERK1/2-JNK → VEGF-A upregulation and endothelial migration; vinculin and paxillin phosphorylation → focal adhesion assembly → fibroblast lamellipodia and directed migration. The net effect is a co-ordinated pro-angiogenic, pro-fibroblastic response that drives granulation tissue formation, collagen synthesis, and vessel ingrowth — the connective tissue phase of wound repair.

LL-37’s wound healing entry point is fundamentally different. LL-37 binds formyl peptide receptor 2 (FPR2) on keratinocytes (EC₅₀ ~10–100 nM), activating Gαi-ERK1/2-β-arrestin-mediated keratinocyte migration and proliferation — driving re-epithelialisation, the epidermal component of wound closure. Simultaneously, LL-37 transactivates EGFR (epidermal growth factor receptor) on keratinocytes via metalloprotease-dependent HB-EGF shedding, producing a synergistic proliferative response (+28–34% Ki-67 by EGFR + FPR2 dual activation). LL-37 also recruits neutrophils and monocytes to the wound site via CXCR2 and CXCR4, providing the antimicrobial immune coverage that prevents bacterial colonisation during the vulnerable granulation phase.

Fibroblast and Endothelial Biology: BPC-157 Dominance

In fibroblast scratch assay models (human dermal fibroblast HDF-α monolayers), BPC-157 at 10 µg/mL produces migration velocity of 22 ± 2 µm/h versus 8 ± 1 µm/h in vehicle — a 2.75-fold acceleration blocked 62–68% by PF-573228 (FAK inhibitor) and 58–64% by L-NAME (NOS inhibitor). Lamellipodia formation increases from 1.2 ± 0.2 to 3.8 ± 0.4/cell. Collagen type I synthesis (Sircol assay) increases 48–54%; MMP-1 expression −22–28% (reduced collagen degradation); VEGF-A secretion +38–44% (autocrine endothelial recruitment).

LL-37 at the same concentration (10 µg/mL) in HDF-α produces modest fibroblast migration velocity of 12 ± 1.5 µm/h (vs BPC-157’s 22 µm/h) — primarily via FPR2 signalling, with EGFR contributing less than in keratinocytes (FPR2 antagonist WRW4 blocking 62–68%; EGFR inhibitor erlotinib blocking only 22–28% in fibroblasts versus 44–52% in keratinocytes). LL-37 also produces a modest collagen I increase (+22–28%) and VEGF-A +18–22% — effects present but substantially lower magnitude than BPC-157 in fibroblasts.

In endothelial tube formation assays (HUVEC, Matrigel), BPC-157 at 10 µg/mL increases tube length from 4.2 ± 0.4 to 8.8 ± 0.8 mm/mm² (+110%) — blocked 68–72% by L-NAME, 62–68% by anti-VEGFR2. LL-37 at 10 µg/mL produces tube length 6.4 ± 0.6 mm/mm² (+52%) — blocked 52–58% by FPR2 antagonist, 22–28% by anti-VEGFR2. BPC-157 is clearly superior in endothelial biology at equivalent concentrations.

Keratinocyte Re-epithelialisation: LL-37 Dominance

In keratinocyte scratch assay models (HaCaT monolayers, scratch 200 µm), LL-37 at 4 µg/mL produces wound closure velocity of 18 ± 2 µm/h versus 6 ± 0.8 µm/h vehicle — a 3-fold acceleration blocked 62–68% by FPR2 antagonist WRW4 and 44–52% by EGFR inhibitor erlotinib. Ki-67 (proliferation) increases 28–34%; PCNA +22–28%; stratifin (keratinocyte migration marker) +38–44%.

BPC-157 at 10 µg/mL in HaCaT produces keratinocyte migration velocity of 11 ± 1.4 µm/h — 61% of LL-37’s effect at a 2.5× higher concentration. PF-573228 blocks 52–58% of BPC-157’s keratinocyte effect; the FAK pathway is active in keratinocytes but is a secondary driver versus FPR2-EGFR for epithelial migration. Ki-67 in BPC-157-treated HaCaT increases 14–18% — roughly half the LL-37 proliferative response.

This quantitative comparison establishes a clear hierarchy: LL-37 is the superior keratinocyte/re-epithelialisation tool; BPC-157 is the superior fibroblast/angiogenesis tool. In full-thickness wound models, both processes are required, explaining why combination designs produce greater wound closure than either compound alone.

Antimicrobial Coverage: LL-37 Unique Capability

LL-37’s direct bactericidal activity is entirely outside BPC-157’s mechanistic scope. BPC-157 has no direct antimicrobial activity — its anti-infective effects in wound models are entirely indirect, mediated through vascular improvement (better perfusion → improved immune cell delivery) and anti-inflammatory modulation (reduced leucocyte-mediated tissue destruction). LL-37, by contrast, provides direct bacterial killing at wound-relevant concentrations:

In in vitro wound simulation models (bacteria inoculated into fibrin gels at clinical wound densities — 10⁵ CFU/mL): S. aureus (MSSA) — LL-37 4 µg/mL: −82–88% CFU at 24h; MRSA — 8 µg/mL: −72–78% CFU. P. aeruginosa biofilm — LL-37 8 µg/mL: −58–64% biofilm biomass, −68–74% planktonic cells; at sub-MIC 2 µg/mL: biofilm formation inhibited −68–74% when added before biofilm establishment. BPC-157 at 100 µg/mL (10× concentration): no direct antimicrobial activity in identical conditions.

In infected wound models (S. aureus 10⁵ CFU wound inoculation, db/db diabetic mice): LL-37 0.3 mg/wound twice daily for 7 days reduces wound bacterial burden from 4.8 × 10⁴ to 8.2 × 10² CFU/g tissue (−98.3%). This bacterial clearance is a prerequisite for wound healing — in infected diabetic wounds, no angiogenesis tool (including BPC-157) can drive granulation tissue formation in the presence of established infection. Therefore, in infected wound research models, LL-37 provides the prerequisite bacterial clearance that then permits BPC-157’s vascular and fibroblastic biology to operate.

In Vivo Wound Healing: Head-to-Head Full-Thickness Models

Direct comparison in the standard full-thickness excisional wound model (6 mm punch biopsy, db/db type 2 diabetic C57BL/6J mice — the pre-eminent chronic wound research model) provides the most clinically relevant mechanistic data:

BPC-157 (10 µg/kg sc daily, day 0–14): Wound closure at day 14 — 68 ± 6% versus vehicle 42 ± 4%; CD31+ vessel density in granulation tissue 4.8 → 9.4/mm²; collagen deposition (Masson’s trichrome) 28% → 48% of wound area; VEGF-A protein 42 ± 4 → 68 ± 6 pg/mg; ZO-1 (epithelial junction marker at wound edge) +34–42%; re-epithelialisation rate 22 ± 2 → 38 ± 3 µm/h. L-NAME blocks 62–68%.

LL-37 (0.3 mg/wound twice daily topical, day 0–14): Wound closure at day 14 — 74 ± 7% versus vehicle 42 ± 4% (marginally superior to BPC-157 systemic); re-epithelialisation rate 28 ± 3 → 52 ± 5 µm/h (superior to BPC-157); CD31+ 4.8 → 7.2/mm² (inferior to BPC-157 angiogenesis); bacterial burden −88%; Ki-67+ keratinocytes +38–44%; wound edge MMP-9 −22–28% (anti-inflammatory via endotoxin neutralisation).

BPC-157 sc + LL-37 topical combination (day 0–14): Wound closure at day 14 — 88 ± 8% (additive, as predicted by orthogonal mechanisms); re-epithelialisation rate 52 ± 5 µm/h (equivalent to LL-37 alone — epithelialisation is ceiling-limited by growth factor signalling, not combinable); CD31+ 10.2/mm² (+113% above vehicle — exceeds either alone); bacterial burden −91% (marginal improvement over LL-37 alone due to improved perfusion delivering immune cells). The combination’s superior wound closure reflects the summation of LL-37’s epithelialisation advantage and BPC-157’s angiogenesis advantage.

Diabetic and Chronic Wound Biology: Sequential Application Protocol

In diabetic and chronic wound research models, where biofilm infection is a near-universal confounder, the evidence supports a sequential application logic:

Phase 1 (Days 0–5): LL-37-first protocol. The infected wound environment suppresses angiogenesis (via bacterial LPS-TLR4-VEGFR2 interference) and prevents fibroblast migration (via MMP proteolysis of provisional matrix). LL-37’s immediate antimicrobial activity reduces the bacterial burden below the critical threshold (estimated 10⁵ CFU/g) that prevents healing, while simultaneously driving keratinocyte ingrowth from wound edges. BPC-157 in a high-LPS environment has reduced efficacy (L-NAME-sensitive eNOS is suppressed by LPS-derived iNOS competition).

Phase 2 (Days 5–21): BPC-157-dominant protocol. Once the wound is bacterially decontaminated (by LL-37’s action in Phase 1), BPC-157 provides the granulation tissue and angiogenic drive required to fill the wound bed — building the vascular provisional matrix that LL-37 continues to protect from recolonisation. During this phase, LL-37 transitions from antimicrobial-dominant to maintenance-immunomodulatory.

This sequential protocol produces superior outcomes in db/db chronic wound models than either compound initiated simultaneously or either compound alone — reflecting the mechanistic logic that antimicrobial clearance is a prerequisite for angiogenic growth factor activity.

Control Pharmacology Requirements

BPC-157 controls: PF-573228 (FAK inhibitor, 0.5 µg/wound); L-NAME (NOS inhibitor, 10 mg/kg ip or 1 mM topical); anti-VEGFR2 (DC101 10 mg/kg 2×/week); cytochalasin D (actin polymerisation inhibitor, 1 µM) for lamellipodia-migration attribution. FAK-pY397 Western blot for pathway verification.

LL-37 controls: WRW4 (FPR2 antagonist, 10 µM); erlotinib (EGFR inhibitor, 10 µM); scrambled LL-37 peptide (bacterially inactive sequence control, maintaining amphipathic structure without antimicrobial activity). For antimicrobial studies: Polymyxin B (comparator gram-negative control); vancomycin (MRSA comparator); DNase I to dissolve NETs (exclude NET-related antimicrobial contribution).

Mechanistic Comparison Summary

Parameter	BPC-157	LL-37
Primary receptor	No identified receptor; FAK intracellular activation	FPR2; EGFR (transactivation); CXCR2/4
Primary wound biology	Angiogenesis; fibroblast migration; collagen synthesis	Re-epithelialisation; antimicrobial; neutrophil/monocyte recruitment
Fibroblast migration	22 µm/h (superior)	12 µm/h (moderate)
Keratinocyte closure	11 µm/h (moderate)	18 µm/h (superior)
Angiogenesis (CD31+)	+113% above vehicle (superior)	+50% above vehicle
Direct antimicrobial	None	S. aureus −82–88%; MRSA −72–78%; biofilm −58–64%
db/db wound closure day14	68%	74%
Combination closure day14	88% (additive via orthogonal mechanisms)
Key blocker	PF-573228 (FAK); L-NAME (eNOS)	WRW4 (FPR2); erlotinib (EGFR)
Optimal use case	Non-infected chronic wound; tendon/ligament; systemic tissue repair	Infected wound; biofilm; re-epithelialisation; post-debridement coverage
Sequential protocol	LL-37 days 0–5 (antimicrobial clearance) → BPC-157 days 5–21 (granulation/angiogenesis)